Previous 10 | Next 10 |
ImmunityBio Inc. (IBRX) is expected to report $-0.27 for Q3 2023
Findings from NCI-led study suggest that Memory Cytokine-Enriched Natural Killer cells (M-ceNK) may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors M-ceNK may provide an additional line of therapy in other cases of immunologically...
2023-10-30 12:16:36 ET DENVER, Colo., Oct. 30, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; VYNE Therapeutics Inc (NASDAQ: VYNE), Coherus BioSciences Inc (NASDAQ: CHRS), MeiraGTx Holdings PLC (N...
2023-10-30 10:00:42 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further...
2023-10-28 03:41:28 ET Summary ImmunityBio is seeking approval for their vaccine Anktiva, which is being assessed for non-muscle invasive bladder cancer. The company faced setbacks with their FDA submission, but recently announced a resubmission that was accepted. ImmunityBio'...
2023-10-27 10:02:45 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further detail...
2023-10-26 12:48:21 ET More on ImmunityBio ImmunityBio: The CRL Makes It Riskier Than Ever ImmunityBio: Ongoing Dilution And Regulatory Uncertainties Blur Investment Prospects ImmunityBio extends gains on surging volumes after regulatory update ImmunityBio an...
2023-10-26 09:56:33 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further detail...
BLA for N-803 plus BCG in high-risk non-muscle-invasive bladder cancer (NMIBC) was resubmitted to the Agency on October 23, 2023 A new PDUFA date of April 23, 2024 has been communicated by the Agency ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today ann...
2023-10-24 14:38:06 ET Summary ImmunityBio, Inc.'s drug Anktiva received a Complete Response Letter, or CRL, from the FDA, delaying its approval for the treatment of NMIBC. The CRL was related to deficiencies in the FDA's inspection of the company's third-party contract manufactur...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...